Abstract:Abstract Background Insulin Resistance (IR) predisposes to cardiometabolic disorders, which are common in schizophrenia and are associated with excess morbidity and mortality. The mechanisms of association remain unknown. We aimed 1) To use genetic data to examine the direction of association between IR and related cardiometabolic risk factors, and schizophrenia; 2) To examine whether inflammation could be a shared mechanism for IR and schizophrenia. Methods We used two-sample uni-variable Mendelian randomization (MR) to examine whether genetically-predicted IR-related cardiometabolic risk factors (Fasting insulin (FI), high-density lipoprotein (HDL), triglycerides (TG), low-density lipoprotein, fasting plasma glucose, glycated haemoglobin, leptin, body mass index, glucose tolerance and type 2 diabetes) may be causally associated with schizophrenia. We used the most recent summary statistics for genetic variants associated with schizophrenia and IR-related cardiometabolic risk factors from publicly-available large genome-wide association studies (GWAS). We used bi-directional MR to examine direction of association. To examine whether inflammation could be a shared mechanism for IR and schizophrenia, we first conducted a sensitivity analysis by performing MR using only cardiometabolic genetic variants that were also associated with inflammation, at genome-wide significance. Second, we used multi-variable MR (MVMR) to examine associations between cardiometabolic risk factors and schizophrenia after adjusting for genetically-predicted levels of C-reactive protein. Results In analyses using all associated genetic variants, genetically predicted levels of leptin were associated with risk of schizophrenia (OR=2.54 per SD increase in leptin; 95% CI, 1.02–6.31). In analyses using inflammation-related variants, genetically predicted levels of FI (OR=2.76 per SD increase in FI; 95% C.I., 1.31–6.17), TG (OR=2.90 per SD increase in TG; 95% C.I., 1.36–6.17), and HDL (OR=0.56 per SD increase in HDL; 95% C.I., 0.37–0.83) were associated with schizophrenia. The associations completely attenuated in MVMR analyses controlling for CRP. There was no evidence of an association between genetically-predicted schizophrenia liability and cardiometabolic factors. Discussion The IR phenotype of FI, TG and HDL could be associated with schizophrenia over and above common sociodemographic and lifestyle factors. This association is likely explained by a common inflammatory mechanism. Interventional studies are required to test whether inflammation could represent a putative therapeutic target for the treatment and prevention of cardiometabolic disorders in schizophrenia.

Insulin Receptor Deficits in Schizophrenia and in Cellular and Animal Models of Insulin Receptor Dysfunction

Neuronal alterations in AKT isotype expression in schizophrenia

Insulin-resistance as a modifiable pathway to cognitive dysfunction in schizophrenia: A systematic review

A Biochemical and Functional Characterization of Diet-Induced Brain Insulin Resistance.

Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia

Hypothalamic serotonin-insulin signaling cross-talk and alterations in a type 2 diabetic model

M88. EVIDENCE FOR INFLAMMATION AS A PUTATIVE SHARED MECHANISM FOR INSULIN RESISTANCE AND SCHIZOPHRENIA

Abnormal Glucose Metabolism and Insulin Resistance Are Induced Via the IRE1α/XBP-1 Pathway in Subclinical Hypothyroidism

Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia

Role of Peripheral and Central Insulin Resistance in Neuropsychiatric Disorders

Effect of Clozapine on Levels of Blood Glucose and Insulin in Patients with Schizophrenia

Association Between SIRT1, Cytokines, and Metabolic Syndrome in Schizophrenia Patients With Olanzapine or Clozapine Monotherapy

Insulin resistance in depression: A large meta-analysis of metabolic parameters and variation

Elevated serum IGFBP-1 levels correlate with cognitive deficits in treatment-resistant and chronic medicated schizophrenia patients

Canonical insulin signaling is not significantly impaired in early stages of depression

Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia

Evaluation of Clinical Correlation between Insulin Resistance and Antipsychotic Drug Therapy in Patients with Schizophrenia

Neuroreceptor Inhibition by Clozapine Triggers Mitohormesis and Metabolic Reprogramming in Human Blood Cells

Insulin Resistance and Cognitive Impairment: Evidence From Neuroimaging

Impaired brain insulin signalling in Parkinson's disease

Fasting and Systemic Insulin Signaling Regulate Phosphorylation of Brain Proteins That Modulate Cell Morphology and Link to Neurological Disorders